Five biotech updates from ESMO: personalized cancer vaccine nears FDA submission
27 October 2026 · filed under 68d48140d486
Moderna and Merck are preparing to submit their personalized cancer vaccine, intismeran, to the FDA, with filing expected in 2027. The update came from Moderna CEO Stéphane Bancel following data presented at the European Society for Medical Oncology (ESMO) meeting this past weekend, as reported by STAT News.
The vaccine is designed to be tailored to an individual patient’s tumor, a departure from conventional one-size-fits-all cancer therapies. STAT News identifies this program as one of five notable biotech updates to emerge from the ESMO weekend, underscoring its position among a broader slate of oncology developments disclosed at the conference.
STAT News reports that Bancel discussed next steps for the vaccine’s regulatory path, framing the anticipated FDA submission as a milestone for the companies’ joint oncology effort. The report does not specify additional detail on trial results, patient population, or regulatory designations beyond the submission timeline attributed to Bancel.
The outlet’s broader roundup, published October 26, 2026, situates the Moderna-Merck update alongside four other biotech items surfacing from the same ESMO proceedings, though specifics of those other four updates are not detailed in the available material. STAT News is the sole cited source for this account.